Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients

European Journal of Cancer Part A

Volumn 33, Issue 6, 1997, Pages 867-872

  Pappot, H ^a,b   Hoyer Hansen G ^a   Ronne E ^a   Hansen, H H ^b   Brunner N ^a   Dano K ^a   Grondahl Hansen J ^a  

^a FINSEN LABORATORY   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

Lung cancer; Plasma; uPAR

Indexed keywords

UROKINASE;

ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; ENZYME PRECURSORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUNG NEOPLASMS; PLASMINOGEN ACTIVATORS; PROGNOSIS; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030799620     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00523-0     Document Type: Article

References (40)

1. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985, 44, 139-266.
2. Blasi F, Vassalli JD, Danø K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 1987, 104, 801-804.
3. Liotta LA, Steeg PS. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64, 327-336.
4. Murphy G, Ward R, Gavrilovic J, Atkinson S. Physiological mechanisms for metalloproteinase activation. In Birkedal-Hansen H, Werb Z, Welgus H, Van Wart H, eds. Matrix Metalloproteinases and Inhibitors. Stuttgart, Gustav Fischer Verlag, 1992, 245-255.
5. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The urokinase receptor. Protein structure and role in the plasminogen activation and cancer invasion. Fibrinolysis 1994, 8, 189-203.
6. Ellis V, Pyke C, Eriksen J, Solberg H, Danø K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann NY Acad Sci 1992, 667, 13-31.
7. Roldan AL, Cubellis MV, Masucci MT, et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990, 9, 467-474.
8. 2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990, 265, 6453-6460.
9. Behrendt N, Ploug M, Patthy L, Houen G, Blasi F, Danø K. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem 1991, 266, 7842-7847.
10. Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F, Danø K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991, 266, 1926-1933.
11. Cubellis MV, Wun TC, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990, 9, 1079-1085.
12. Olson D, Pollänan J, Høyer-Hansen G, et al. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex mediated by the urokinase receptor. J Biol Chem 1992, 267, 9129-9133.
13. Nykjær A, Petersen CM, Møller B, et al. Purified alpha-2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasmingen activator inhibitor type-1 complex. Evidence that the alpha-2-macroglobulin receptor mediates cellular degradation of urokinase receptor bound complexes. J Biol Chem 1992, 267, 14543-14546.
14. Sappino AP, Busso N, Belin D, Vassali J-D. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 1987, 47, 4043-4046.
15. Gris J, Schved J, Marty-Double C, Mauboussin J, Balmes P. Immunohistochemical study of tumor cell associated plasminogen activators and plasminogen activator in lung carcinomas. Chest 1993, 104, 8-13.
16. Veale D, Needham G, Harris AL. Urokinase receptors in lung cancer and normal lung. Anticancer Res 1990, 10, 417-422.
17. Pedersen H, Grøndahl-Hansen J, Francis D, et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994, 54, 120-123.
18. Pedersen H, Brünner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994, 54, 4671-4675.
19. Rønne E, Høyer-Hansen G, Brünner N, et al. Urokinase-type receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono-and polyclonal antibodies. Breast Cancer Res Treat 1995, 33, 199-207.
20. Rønne E, Pappot H, Grøndahl-Hansen J, et al. The receptor for urokinase type plasminogen activator is present in plasma from healthy donors and elevated in patients with nocturnal haemoglobinuria. Br J Haematol 1995, 89, 576-581.
21. Rønne E, Behrendt N, Ploug M, et al. Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. J Immunol Meth 1994, 167, 91-101.
22. 2-terminal domain of the urokinase receptor. FEBS Lett 1991, 288, 233-336.
23. Bordier C. Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem 1981, 256, 1604-1607.
24. Pedersen N, Schmitt M, Rønne E, et al. A ligand-free soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993, 92, 2160-2167.
25. Høyer-Hansen G, Rønne E, Solberg H, et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand binding domain. J Biol Chem 1992, 267, 18224-18229.
26. Solberg H, Rømer J, Brünner N, et al. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumours. Int J Cancer 1994, 58, 877-881.
27. Ploug M, Eriksen J, Plesner T, Hansen NE, Danø K. A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leucocytes from patients with paroxysmal nocturnal haemoglobinuria. Eur J Biochem 1992, 208, 397-404.
28. Ehlers MR, Riordan JF. Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins. Biochemistry 1991, 30, 10065-10074.
29. Kristensen P, Pyke C, Lund LR, Andreasen PA, Danø K. Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry 1990, 93, 559-566.
30. Pyke C, Kristensen P, Ralfkiær E, Eriksen J, Danø K. The plasminogen activation system in human colon cancer; messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 1991, 51, 4067-4071.
31. Pappot H, Brünner N. The plasminogen activation system and its role in lung cancer. Lung Cancer 1995, 12, 1-12.
32. Duffy MJ, Reilly D, O'Sullvan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990, 50, 6827-6829.
33. Foekens J, Schmitt M, van Putten WLJ, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992, 52, 6101-6105.
34. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993, 53, 2513-2521.
35. Nekarda H, Siewert JR, Schmitt M, Ulm K. Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 1994, 117, 343.
36. Ganesh S, Sier CFM, Griffioen G, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994, 54, 4065-4071.
37. Mulsahy HE, Duffy MJ, Gibbons D, et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994, 344, 583-584.
38. Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y, Simiyosho A. The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer. J Urol 1994, 151, 16-20.
39. Grøndahl-Hansen J, Peters H, van Putten WLJ, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995, 1, 1079-1087.
40. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994, 344, 401-402.